Canada markets closed

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.5700-0.2500 (-6.54%)
At close: 04:00PM EDT
3.6200 +0.05 (+1.40%)
After hours: 05:32PM EDT

Graphite Bio, Inc.

201 Haskins Way
Suite 210
South San Francisco, CA 94080
United States
650 484 0886
https://www.graphitebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees111

Key Executives

NameTitlePayExercisedYear Born
Dr. Joshua Lehrer-Graiwer FACC, M.D.Pres, CEO & Director724.58kN/A1974
Dr. Matthew Porteus M.D., Ph.D.Academic Founder & Director90.77kN/A1965
Dr. Maria Grazia Roncarolo M.D., Ph.D.Academic Founder & Chair of Scientific Advisory Board70kN/A1954
Mr. Philip P. GutryChief Bus. Officer541.33kN/A1973
Dr. Daniel Dever Ph.D.Co-Founder & Head of Discovery ResearchN/AN/AN/A
Ms. Alethia Rene YoungChief Financial OfficerN/AN/A1979
Dr. Christine Garrett P.M.P., Ph.D.Chief of Staff & Sr. VP of OperationsN/AN/A1971
Mr. Jerry CaciaChief Technical OfficerN/AN/A1967
Dr. Jane Grogan Ph.D.Chief Scientific OfficerN/AN/A1968
Stephanie YaoVP of Communications & Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Graphite Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.